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MECHANISTIC STUDIES ON THE ANTAGONISTIC EFFECT OF
CHROMIUM ON BPDE MUTANT FREQUENCIES IN
HUMAN FIBROBLASTS
Felicia Codrea, M.A.
Western Michigan University, 2002
The purpose of this study was to investigate the possible mechanisms involved
in the decrease in mutant frequency when cells are treated with two different types of
carcinogens: chromium (VI) in combination with benzo(a)pyrene diol epoxide
(BPDE). Three of our working hypotheses are: Cr alone or Cr and BPDE
synergistically activate detoxifying enzyme glutathione-S-transferase (GST), Cr alone
or Cr and BPDE act synergistically to inhibit cell cycle at the G 1 /S boundary thus
allowing more time for DNA repair, and Cr alone or Cr and BPDE synergistically
activate DNA repair systems which result in more efficient repair of DNA adducts.
The results from experiments measuring GST activity show that the activity of
the enzyme is not influenced by the different treatments with carcinogens. The results
for the experiments related to cell cycle arrest show that entry into S phase occurs at
the same time for all conditions.
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CHAPTER I
INTRODUCTION
Cancer and Carcinogenesis
Cancer is a disease in which cells acquire many abnormal characteristics, one
of which is uncontrolled growth. In molecular terms, cancer is a disease of abnormal
gene expression. Even though this disease has been known for a long time, there is
still a great deal to discover. The term cancer is a general one since it is well known
that there are many forms in which this disease is manifested. Scientists have
observed that there are some chemicals that cause this disease. Those substances are
called carcinogens. Historically, one of the first examples of environmental
carcinogenesis was reported in 1775 and involved tumor induction in workers
exposed to coal tar (Miller et al., 1975).
Carcinogenesis, the transformation of a normal cell to a tumor cell, is a
multistep process, usually taking a long period of time (20 years or more) to
complete. The human adult is composed of approximately 10 15 cells, many of which
must divide and differentiate in order to repopulate organs and tissues. There are very
elaborate mechanisms for controlling cell proliferation on one side and cell death, or
apoptosis, on the other side. It is clear now that if mutations occur in the genes which
control gene proliferation, cancer can be the result (Bertram, 2001 ).
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One primary cause of carcinogenesis is mutation of genes critical for normal
cell function. DNA is subject to damage from exogenous agents both chemical and
physical. The most frequent chemical reaction giving rise to DNA damage can be
characterized as an electophilic attack upon a nucleophile (Miller et al., 1975). The
most frequent base that undergoes this kind of damage is guanine.
It is important to understand that damage to DNA may not be mutagenic itself.
Subsequent DNA replication and cell division is often necessary for a mutation to
appear. For example, if one carcinogenic molecule binds to a DNA strand at one
guanine base, the DNA polymerase will not recognize the complex formed as a
normal guanine base during DNA replication. Instead of matching the guanine with a
cytosine, the newly synthesized complementary strand may contain a different base
(may be any of the four bases A, G, C, or T). Another possibility of damaged DNA is
when deletions of some bases occur.
There are many types of carcinogens, and substances from different classes of
chemicals cause cellular damage in different ways. It is known that carcinogens, like
chemicals found in the environment and radiation, can cause chromosomal mutations
leading to abnormal cell function. For example, ionizing radiation can cause direct
damage to DNA, including single and double-strand breaks, and also indirect damage
as a consequence of radiolysis of water to yield free radicals (Hall et al., 1999). UV
light produces DNA damage by a variety of mechanisms, including the formation of
oxygen radicals. It can also generate photoaddition products, especially at adjacent
pyrimidines. Formation of a cyclobutane pyrimidine dimmer including CS and C6
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bond is one of the most common adducts, along with 6-4 photoproducts (Fig. 1) (Mol
et al., 1999). Both lesions can cause cellular death by blocking replication or
transcription, or induce mutations, which may result in cancer. Sunlight-induced skin
cancer from UV exposure is one of the most common forms of cancer.
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Fig. 1. Structures of UV Photoproducts.
Another example of environmental carcinogenesis, but this time from a
chemical carcinogen, is highlighted in the epidemiological studies of Langard et al.
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(Langard et al., 1990). These investigators have shown that industrial workers
exposed to Cr (VI) develop more respiratory cancers than the control population.
Chromium Carcinogenesis
Chromium is an essential nutrient for mammalian carbohydrate and lipid
metabolism. Vincent reported that there is a strong relationship between glucose
metabolism and chromium intake, probably related to insulin action. At a molecular
level, a key role is played by the oligopeptide chromodulin (Vincent, 2001). The daily
dose of chromium should be between 50 and 200 µg. Some symptoms of insufficient
intake of chromium are hypoglycemia, glycosuria, elevated circulating insulin,
decreased insulin binding, and increased ocular pressure (Anderson et al., 1997).
Nutritional studies showed that trivalent chromium it is not toxic up to 1 mg per day.
Cr (III) can be harmful, however. It was reported that upon skin contact, certain Cr
(III) compounds can cause irritations and allergies in some sensitive people (Miksche
et al., 1997).
It is already well known that some chromium compounds, especially Cr (VI),
are human carcinogens (De Flora et al., 1990). The greatest exposure to chromium is
occupational, which may take place in the metal refining/chromate industry,
metallurgic industry, and also in steel and anticorrosive paint production (U.S. Public
Health Service, 1953). Environmental chromium is mobilized through the combustion
of fossil fuels, incineration of public garbage, and also contamination of water and
land with industrial chromate waste (Burke et al., 1991). The gate of entry of Cr (VI),
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as potassium dichromate, into mammalian cells is via general arnon transport
channels since the chromate anion is very similar in structure to sulfate and phosphate
anions. The most affected tissues from chromium (VI) exposure are the skin, the
respiratory tract, and the kidneys (Miksche et al., 1997). The effects of chromium
(VI) on different organs can be seen in Table 1.

Table 1. Effects of Chromium (VI) on Different Organs.
Organ

Effect

Skin

Dermatitis, Sensitization, Chromium ulcers

Nose

Septal irritation, Septal ulcer, Septum perforation

Lungs

Irritation, Bronchitis, Carcinoma

Kidneys

Tubular dysfunction

The toxic effect of chromium is due to the reduction of the Cr (VI) ion to the
more reactive intermediates Cr (V) and Cr (IV), and to the stable Cr (III), by a
spectrum of reductants including glutathione (GSH), cysteine, ascorbate, riboflavin
and NADPH-dependent flavoenzymes like microsomal cytochrome P450 reductase
(Shi et al., 1999, De Flora et al., 1990, Sugiyama, 1992). Cellular reduction of Cr (VI)
is represented in Fig. 2. (Sugiyama, 1991).
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The reduced chromium can then increase the concentration of hydroxyl
radicals in cells via the Fenton reaction pathway. Cr (V), which is unstable, reacts
with hydrogen peroxide as shown below:

+

Cr3

V
Enzyme inhibition

Cr(V)
---+---- Cr (VI)-Reductive metabolism Glutathione
Ascorbate
Hydrogen peroxide
Flavoenzymes
Others?

Cr(IV)

- DNA damage

Cr(III)

Chromosomal
aberration

-OHradicals
GS-

Fig. 2.Cellular Reduction of Cr (VI). Modified from Sugiyama, M. (1991).

Cr (V)+H2O2---------> Cr (VI)+ ·OH+ Of

f

Cr (VI) can be reduced by glutathione and ascorbic acid and generate Cr (IV) which
is able to generate ·OH formation via a Fenton-like reaction (Luo et al., 1996):
Cr (IV)+H2O2---------> Cr (V) +OH+ OHThe generation of the hydroxyl radical ("OH) and lipid hydroperoxide derived free
radicals from the reaction of Cr (III) with H2O2 has also been reported (Shi et al.,
1993). The hydroxyl radicals formed are dangerous because they can react with DNA
and cause base damage, such as 8-hydroxydeoxyguanosine (Fig. 3), which if left
unrepaired can form point mutations (Aiyar et al., 1989). It has also been shown that
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exposure to chromium can lead to both DNA-protein cross-linking and DNA-DNA
cross-linking which can result in mutations in cellular genes (Leibross et al., 1990).
Chromium can also induce DNA damage by formation of Cr-DNA adducts (Wu et
al., 2001).
,J::1/0H

H

dR

Fig. 3. Structure of 8-Hydroxydeoxyguanosine (Wang et al., 1998).
Benzo(a)pyrene Carcinogenesis
Benzo(a)pyrene is a common environmental pollutant that belongs to a class
of chemicals called polyaromatic hydrocarbons (PAH). Benzo(a)pyrene can be
found in cigarette smoke, fuel exhaust, and any time there is incomplete combustion
of organic matter. Benzo(a)pyrene itself is not carcinogenic, but it gets metabolized to
benzo(a)pyrene-(7R,8S)-diol (9S,10 R)-epoxide ((+)-anti-BPDE) once it gets into the
body. This product is the result of epoxidation, hydration, and further epoxidation of
the benzo(a)pyrene (Sanjay et al.,1999). BPDE exists as a pair of diastereoisomers
(syn- and anti- BPDE) and each has a pair of optical enantiomers (Fig. 4). The most
carcinogenic from of these isomers was found to be the (+) anti-BPDE with a (R, S)
diol (S, R) epoxide configuration. It was shown in previous studies that (+) anti
BPDE induces approximately 22 to 59-fold more mutations than the other three
isomers (Hong et al., 1998).
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BPDE is carcinogenic due to eletrophilic attack on the nucleophilic sites of
DNA (and also RNA and proteins), which forms a covalent, bulky carcinogen-DNA

OH

(+) anti-BPDE

OH

(+)- syn- BPDE

OH

(-) anti-BPDE

OH

(-) - syn-BPDE

Fig. 4. Structures ofBPDE Isomers (Hu et al., 1997).
adduct. The primary product of the reaction of (+)-anti-BPDE with DNA, is the (+)
trans-anti-benzo(a)pyrene diol epoxide-N2-dG adduct (Fig. 5) (Perlow et al., 2001). It
is the most mutagenic benzo(a)pyrene adduct in mammalian systems, and causes G-T
transversion mutations (Denissenko et al., 1998) because the DNA polymerase does
not recognize the bulky adduct as guanine and will mismatch the adduct with adenine
during replication. This may happen because the size and shape of adenine opposite
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syn (+)-trans-anti benzo(a)pyrene -N2 -deoxyguanosine is similar to that of a WastonCrick pair (Perlow et al., 2001 ).

OH

Fig. 5. The Structure of the (+)-Trans-Anti-Benzo(a)pyrene Diol Epoxide-N2-dG
Adduct (Perlow et al., 2001).
Multiple Carcinogen Treatment

The literature is filled with information about different carcinogens and how
exposure can lead to cancer. Most of these studies, however, concentrate on only one
substance. In real life, the human body is exposed to a multitude of carcinogens
simultaneously. The overall goal of this project is to examine the cellular effect of
multiple carcinogen treatments. For this study, we have chosen two different types of
carcinogens: chromium (VI) and the polycyclic aromatic hydrocarbon benzo(a)pyrene
diolepoxide (BPDE).
Initial experiments were performed by others in the lab to determine the effect
of multiple carcinogen treatment on mutant frequencies (Tesfai et al., 1998). Cloning
experiments were performed to establish the appropriate concentration of
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carcinogens. The cytotoxicity was determined by plating 300 cells/dish in 100 mm
tissue culture dishes. Cells were treated for 48 hours with different concentrations (0,
0.01 µM, 0.03 µM, 0.1 µM, 0.3 µM, and 1 µM) of potassium dichromate (K2Cr2O1).
The chromium containing medium was then replaced with a medium without
chromium and the cells were allowed to grow for two weeks. The dishes were then
stained with crystal violet and the number of clones was determined. Triplicate dishes
were used for each concentration. Based upon the results of the experiments, and
according to the existing literature, 0.3 µM K2Cr2O1 was chosen because it produced
approximately a 50% decrease in cloning. Typically, concentrations of carcinogens
which show significant decreases in cloning ability are needed in order to observe
mutations. BPDE was also tested and a concentration of 0.3 µM and an incubation
time of 2 hours was chosen.
Four conditions were established in initial experiments. Cells were treated
with either normal growth media for 48 hours (control), media containing 0.3 µM
potassium dichromate for 48 hours, normal growth media for 46 hours followed by
media containing 0.3 µM BPDE for 2 hours (BPDE), or 46 hours with media
containing 0.3 µM potassium dichromate followed by 2 hours with media containing
both chromium and BPDE together. Cytotoxicity was determined using the cloning
method described above and reported as relative cloning ability with the untreated
controls defined as 100%. Results of this part of the experiment are shown in Fig. 6
(Tesfai et al., 1998). When the cells were treated with both carcinogens there was a
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decrease in cloning ability of the cells when compared to the results of individual
treatments which appeared to be additive.

.....>-

100

C
C
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50

25
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Cr

BPDE

Both

Fig. 6. Effect of Pretreatment with Cr (VI) Followed by Coincubation with BPDE on
Cellular Cloning Ability.
The mutant frequency at the hypoxanthine phosphoribosyltransferase (HPRT)
gene was done by incubating cells with the carcinogen(s), as described above, and
then allowing the cells to grow in normal growth media without carcinogens for 10
days following treatment. The cells were then replated in 30 µM 6-thioguanine.
Normal cells will metabolize this compound into a toxic substance via the enzyme
synthesized from the HPRT gene and not grow. If the HPRT gene is mutated, cells
will not metabolize the 6-thioguanine and be able to grow. Cells were allowed to
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grow in presence of 6-thioguanine for 3 weeks, then dishes were stained with crystal
violet and the number of mutant clones counted and corrected for cloning efficiency.
When cells were coincubated with both carcinogens, an antagonistic effect on mutant
frequency was observed (Fig. 7). It appeared that the chromium treatment protected
the cells from the mutagenic effects of the BPDE.
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Fig. 7. Effect of Pretreatment with Cr(VI) Followed by Coincubation with Cr (VI) on
Mutant Frequency ofBPDE.
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The question was then raised as to whether the order of adding the two carcinogens
influenced the results. Therefore, three different protocols were tested and the results
compared to those stated above. The three additional protocols tested were:
1. 48 hours chromium +2 hours BPDE
2. 2 hours coincubation Cr and BPDE + 46 hours chromium
3. 2 hours BPDE +48 hours chromium
The results from protocol one showed that chromium had an additive effect on
the cytotoxicity of BPDE as described for the previous protocol. When cells were
pretreated with chromium before BPDE treatments, the mutant frequency was much
higher than when cells were treated only with BPDE. It seemed that the two
carcinogens acted synergistically. The results of the second treatment protocol were
similar to that obtained with the original treatment schedule (Fig. 6 and Fig. 7). It
appeared that chromium protected the cells from the mutagenic effect of BPDE but
still maintained the additive effect when cytotoxicity was determined. In the last
protocol, the antagonistic effect of chromium on mutant frequency of BPDE was lost
with no synergistic effect observed, but the additive effect on cytotoxicity was still
present.
The conclusion from this set of experiments is that the order of addition of
carcinogens does not affect the results of the cloning ability experiments, but the
antagonistic effect of chromium on the HPRT mutant frequency by BPDE was seen
only when the two carcinogens were coincubated. This antagonistic effect on mutant
frequency seems to be due to the formation of reactive oxygen species (ROS). When
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the experiments were performed using vitamin E (antioxidant) in the media, the
antagonistic effect of the metal was completed eliminated. The purpose of this study
is to elucidate the biochemical mechanism for this antagonistic effect.
Hypotheses
We have proposed the following hypotheses to explain the antagonistic effect
on the mutant frequency described above:
1. Chromium alone or chromium and BPDE synergistically activate the
enzyme glutathione S-transferase (GST). This enzyme has been shown to inactivate
many polyaromatic hydrocarbons by reacting them with glutathione.
2. Chromium alone or chromium and BPDE synergistically halt the cell
cycle progression at the G 1 /S boundary and allow the cells more time to repair DNA
BPDE adducts.
3. Chromium alone or chromium and BPDE synergistically activate DNA
repair systems which result in more efficient repair of DNA adducts.
BPDE Detoxifying Enzymes
There are many enzymes involved in defense mechanisms to protect cells
against toxic compounds. The metabolism of xenobiotic compounds can be
characterized as taking place in two distinct phases, commonly referred as phase I and
phase II. Usually in phase I a xenobiotic undergoes a transformation, which can be
oxidation, reduction, and/or hydrolysis. Oxidation is the dominant reaction and the
enzyme which catalyzes this process is cytochrome P450. In phase II, the xenobiotic
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or its metabolite is conjugated to an endogenous molecule. These conjugation
reactions are catalyzed by different detoxifying enzymes, like epoxide hydrolases
(EH) (Siedegard et al., 1997), sulfotransferases (SULT), UDP-glucuronosyl
transferases (UDPGT) (Iersel et al., 1999), and glutathione S-transferase (GST)
(Hayes et al., 1995). The conjugation products have- lower reactivity compared to the
toxic compounds and can be excreted from the cell and the body.
Several systems have been developed by mammalian cells that detoxify BPDE.
Addition of water to the epoxide moiety of BPDE, to form the corresponding
benzo(a)pyrene-7,8,9,10-tetraol, is catalyzed by epoxide hydrolase (Penning, 1993)
(Fig.8). When BPDE is metabolized with the help of sulfotransferase it forms sulfate
conjugates

(Penning,

1993)

(Fig.9).

When

BPDE

1s

detoxified

by

glucuronosyltransferase, the conjugation reaction formation of conjugates between
reactive hydroxyl groups and glucuronic acid (Penning, 1993) (Fig. 10).

HO

EH

OH
OH

BPDE

►

OH
B(a)P-7,8,9,10-tetraol

Fig. 8. Formation ofBenzo(a)pyrene-7,8,9,10-tetraol by Addition of Water to BPDE.
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OH

BPDE

Sulfate conjugate

Fig. 9. Detoxification ofBPDE by Sulfotransferase.

OH

BPDE

Glucuronosyl conjugate

Fig. 10. Detoxification ofBPDE by UDP-glucuronosyl Transferase.
The glutathione S-transferases (GST) are a family of multifunctional
enzymes important for cellular detoxification (Vanhaecke et al., 1997). They catalyze
the conjugation of eletrophilic compounds with the glutathione via the thiol group of
cysteine (Habig et al., 1974). The conjugation product is exported from the cell via an
ATP -dependent efflux pump (Wilce et al., 1994) and then excreted. The cytosolic
GST activity of mammalian cells is due to a multitude of isoenzymes designated as
alpha, mu, pi, sigma and theta families.
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GST also plays an important role in reducing the effects of reactive oxygen
species (ROS) and the breakdown products of oxidized DNA (Hayes et al., 1995).
Glutathione may play an important role in the protection against oxidative stress
induced by metals since it has been shown that Cr(VI) induces high levels of GST
(Dubrovskaya et al., 1998, Kitahara et al., 1984). Studies done by Tully and
coworkers showed that Cr(VI) produces dose-related two-fold induction of GST Ya
in human hepatoma cells HepG2 (Tully et al., 2000). Glutathione S-transferase was
also shown to play an important role in eliminating the effect of reactive oxygen
species generated by Cr (VI), by reacting the products of ROS with glutathione
(Kortenkamp et al., 1996). Reduced glutathione (GSH) manifests a high reactivity
towards Cr(VI)(Wiegand et al., 1984) and it was shown that this plays an important
role in Cr(VI) metabolism.
It has been demonstrated that purified GST reduces the binding of BPDE to
DNA(Hesse et al., 1982). It was also shown that purified human pi-class isoenzymes
are more efficient than other classes in binding GSH with(+)-anti-BPDE(Xia et al.,
1998). In addition (-)-anti-BPDE is a poor substrate for hGSTPl-1 compared to(+)
anti-BPDE (Fig. 11) (Hu et al., 1997). Fields et al. showed that high levels of
expression of h-GSTPl-1 were protective against DNA damage and cytotoxicity
induced by BPDE (Fields et al., 1988). Other studies have shown that hGSHTMl-1
the human mu isoenzyme, is believed to play an important role in detoxifying (+)
anti-BPDE(Srivastava et al., 1999). GST is induced by high levels of BPDE(Hayes
et al., 1995). Since it was shown that GST is induced by both, chromium(VI) and
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BPDE, we chose to test if this enzyme is activated when there is coincubation of the
two carcinogens.

GSH
GST
HO

�{

OH
OH

(-)- (7R, 8S, 9S, 10S)-BPDE
[(-)-anti-GS-BPDE]

(+)- (7R, 8S, 9S, lOR)-BPDE
[(+)-anti-BPDE]

GSH
GST
OH

(-)- (7S, 8R, 9S, 10S)-BPDE
[(-)-anti-BPDE]

OH

(+)-(7S, 8R, 9R, lOR)-BPDE
[(+)-anti-BPDE]

Fig. 11. Structure of Anti-BPDE Enantiomers and their Conjugates with GSH. (Hu et
al., 1997).
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Cell Cycle
The cell cycle is the period of time from the birth of one cell to the point when
the cell divides into two daughter cells. The cell cycle is regulated by a succession of
events, and is divided into four phases (Fig. 12):
G1 initial growth phase or gap phase
S synthesis of DNA
G2 another gap phase
M mitosis (cell division) for somatic cells.

Fig. 12. Phases of the Cell Cycle.

After mitosis, cells can enter into a resting state (Go), or when receiving
appropriate growth signals, enter again into G1 phase (Tyrcha, 2001). There is
another alternative, and that is the cell may receive signals that trigger cell death or
apoptosis. The cell cycle is very important because the genetic information is
preserved and transferred to the new cells (Dictor et al., 1999). There are several
checkpoints in the cell cycle to make sure that the genetic integrity of the genome is
preserved. All phases of the cell cycle are subject to checkpoint control. One of the
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most important checkpoints occurs in late G1, about four hours prior to entry into S
phase, when the DNA is replicated. Its role is to ensure that the cell does not begin
DNA synthesis if the DNA is not integer (Bertram, 2001). If the DNA is damaged,
there is a halt at the G1/S boundary until the DNA repair mechanisms fix the damage
or apoptosis is triggered (Sielecki et al., 2000).· Once the cell passes the G1/S
checkpoint, it is irreversibly committed to the next division cycle.
One of the key proteins involved in cell cycle progression into the S phase
is the retinoblastoma protein pRb. In its unphosphorylated form, pRb binds to E2F (a
family of transcription factors) and forms a silencing complex restricting transcription
of genes necessary for cell cycle progression (Weintraub et al., 1995). Key enzymes
also include cyclin-dependent kinases (CDKs). They are polypeptides that consist of a
heterodimer, one catalytic subunit which has no intrinsic activity and one regulatory
subunit called cyclin (Hengstschlager et al., 1998). Cyclins are so named because
they are synthesized only at a specific time of the cell cycle. The activation of the
catalytic subunit occurs in a two-step process (Pavletich, 1999). The first step is
association with a cyclin regulatory subunit for activity (Sielescki et al., 2000). This is
a very important step because the cyclin levels are strongly regulated by transcription
and ubiquitin mediated degradation in a temporal manner (Morgan et al., 1995). The
second step is the phosphorylation of the CDK-cyclin complex by the CDK
activating kinase (CAK) (Fisher et al., 1994). The function of the CDK-cyclin
complex is to phosphorylate or dephosphorylate specific serine or threonine residues
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on target proteins, like retinoblastoma protein, using ATP as a phosphate group
source (Sielecki et al., 2000).
There are several cyclins and associated proteins that are involved in the
cell cycle and the G1/S transition. Two complexes of interest are formed between
cyclin D and CDK 4 and cyclin D and CDK 6 (Fig. 13). Their target is the
retinoblastoma pRb protein (Grana et al., 1998, Ekholm et al., 2000). Also cyclin E
forms a complex with CDK2, and has a secondary role in phosphorylating the pRb
(Draetta, 1994, Harbour et al., 1999). The activity of cyclin dependent kinases is
inhibited by the INK family of proteins, which bind to CDKs and inhibit the
formation of cyclin-CDK complex. In addition, the p21 family, which contains p21
WAFl/CIPl/CDKl, p27 KIPl, and p57 KIP2, inhibits the cyclin-CDK complex
formation

(Dieter

et

al.,

1999).

An

important

role

m

the

phosphorylation/dephosphorylation state of pRb is played by the tumor suppressor
protein p53. Tumor suppressor genes are genes that control cell growth and can be
inactivated by mutations (Bertram, 2001).

The p53 pathway is induced by a

multitude of factors, like DNA damage and oxidative stress (Liu et al., 2001). DNA
damaging agents like y irradiation, ultraviolet light, or chemical carcinogens can
activate p53. This is accomplished by phosphorylation of serine 15 and/or serine 20
of the transactivation domain and both phosphorylation and acetylation of the basic
allosteric control region (Giaccia et al., 1998, Lakin et al., 1999, Hickman et al.,
2002). The p53 protein activates p21, which inhibits the function of cyclin D:
CDK4/CDK6 complex (Fig. 13).
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Carcinogen

p53

p21

Complex Cyclin D: CDK4/CDK6

pRb:E2F

phosphorylation of pRb

pRbP04 + E2F

Gene Expression
Fig. 13. Cascade of Events at the G 1 /S Boundary (Modified from Dictor et al., 1999).

It is reasonable to imply that after carcinogen treatment, the cell cycle will be
delayed and the DNA repair mechanisms will be triggered. Xu et al. showed that
chromium blocks the cell cycle at the G 1 /S boundary (Xu et al., 1996). p53, playing
such an important role not only in progression of the cell cycle but also in DNA repair
systems (Nagata, 1997, Albrechtsen et al., 1999), may be synthesized in higher
concentrations after carcinogenic stress. The p21 protein would then be activated by
p53.

CHAPTER II
MATERIALS AND METHODS
Cells and Cell Culture
One cell line used throughout this study was L266-C, a normal human
fibroblast cell line derived from human foreskin tissue. It was provided by Dr. Justin
McCormick of the Carcinogenesis Laboratory at Michigan State University. Cells
with a passage number of 30 or less were used in the reported experiments. The
fibrosarcoma cell line HT1080, also obtained from Dr. McCormick, was used for the
validation of the glutathione S-transferase assay. Cells were grown in medium
composed of Dulbecco's Modified Eagle's Medium (DMEM) (Gibco/BRL)
supplemented with 0.2 mM serine, 0.2 mM aspartate, and 1.0 mM sodium pyruvate
and containing 10% supplemented calf serum (SCS) (Summit Biotechnologies),
penicillin (100 units/ml), streptomycin (100 µg/ml) and hydrocortisone (10 µg/ml).
Cells were incubated in a humidified atmosphere at 37°C with 5% CO2•

Cell Harvesting and Counting
Cells were washed with phosphate buffer saline (PBS), then treated with a
0.25% trypsin solution in PBS for 4-5 minutes for L266-C cells and 1-2 minutes for
HTl 080 cells. Cells were washed off plates or flasks using 5 ml of complete medium
and counted using a hemocytometer when necessary. The cell counts were determined
for plating the appropriate cell density for the incorporation of 3H-thymidine in the
DNA labeling experiments, or for normalizing the data for the glutathione S23
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transferase activity assay. We could not use the total amount of protein for
normalization in the glutathione S-transferase assay due to the fact that BSA was
added to each sample.

Chemicals Used
The

(+)-r-7,t-8-dihydroxy-t-9,1O-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene

(BPDE) was purchased from ChemSym Science Laboratories. A 1.0-mM stock
solution of BPDE in DMSO was prepared freshly for each experiment. Potassium
dichromate was purchased from Spectrum Chemical Manufacturing and a 1.0 mM
stock solution in PBS was prepared, sterile filtered and stored at 4°C. The stock
solution of each carcinogen was diluted with the complete medium to the
concentration of 0.3 µM for each treatment.

Glutathione S-transferase Assay
Initially, cells were plated onto 150 mm dishes at low density. The cells were
allowed to grow, and then treated with or without carcinogens when they had reached
approximately 50% confluence. Treatment was done at this time so that we had the
maximum number of logarithmically growing cells to assay. After the appropriate
incubation period, cells were trypsinized, collected in 5ml PBS containing lmg/ml
BSA and centrifuged at 900 rpm for 3 min at 4°C using a Beckman centrifuge. It was
necessary to add BSA to the buffer to help the cells pellet upon centrifugation. The
pellets were resuspended in 500 µl PBS and lysed either by sonication or a
freeze/thawing method. Before sonication or freeze/thawing, a 50 µl aliquot of each
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sample was saved for counting to normalize the results to the number of cells. After
sonication, or freeze/thawing, the cell lysate was centrifuged at 14,000 rpm for 40
minutes at 4°C and the supernatant collected.
For the spectrophotometric readings, the instrument was blanked using a
solution containing 960 µl 0.2 M phosphate buffer {pH 6.5) and 40 µl 95% ethanol.
Next, three readings were taken using only 860 µl phosphate buffer, 100 µl reduced
glutathione (10 mM in phosphate buffer, pH 6.5) and 40 µl CDNB (25 mM in
ethanol). Since this reaction mixture contains no enzyme, we expect no activity. The
average of those three readings was substracted from the readings of samples
containing cell lysates. For each sample, 100 µl of cell lysate was added to a mixture
of 760 µl phosphate buffer, 100 µl reduced glutathione (10 mM stock solution) and
40 µl CDNB (25 mM-stock solution) (Dubrovskaya et al., 1998, Hu et al., 1999). The
absorbance at 340 nm was then determined for 3 minutes using a Beckman DU-7400
spectrophotometer. Three different readings were taken for each condition,
normalized for the number of cells, and expressed as units of enzyme activity per cell,
per minute. One unit of activity corresponds to an absorbance change of 3.2 O.D./min
and is defined as formation of 1 µmol/min of thioether (Simons et al., 1977).
DNA Labeling Assay
Experiments determining cell cycle arrest were performed by measuring the
incorporation of 3 H-thymidine into DNA. L266-C cells were plated in 100 mm dishes
and grown to confluence. After the cells reached confluence they were refed daily
with medium containing serum for three additional days, and then not fed for 36 hours

following the final medium change. Cells were designated to be in the G0 state at this
time. Cells were then treated with or without 0.3 µM K2Cr2O7, and after 36 hours of
treatment, the cells were replated in the appropriate medium (with or without
K2 Cr2 O7) at 104 cells/cm2 in 30 mm dishes (24 dishes for each condition). The cells
were incubated for 10 hours, and then the appropriate addition of BPDE and/or Cr
(VI) was made (see four conditions in the Introduction). The cells were incubated for
an additional 2 hours and then all medium was replaced with fresh medium
containing no carcinogens. The first time point was immediately after the carcinogens
were taken off (12 hours after release from G0). Every 4 hours, beginning with the
initial time point, the media was aspirated off 3 plates and replaced with 1 ml of
media per plate containing 3H-thymidine (5 µCi/ml). The cells were then incubated
for 15 minutes in the presence of the labeled thymidine, washed with PBS,
trypsinized, an aliquot of 50 µl counted to determine the number of cells, and the
remainder collected on a Whatman filter. The filter was washed twice with
hypochloric acid (10%) and twice with 95% ethanol to eliminate unincorporated 3H
thymidine. The filter paper was allowed to dry and the radioactivity bound to the filter
was determined by liquid scintillation counting (Watanabe et al., 1985). The extent of
incorporation was corrected for the number of cells assayed and it was expressed as
counts per minute per 100,000 cells.

Western Blotting Assay
Lysates from cells treated in various ways were prepared by washing the cells
with ice cold PBS and scraping the cells off the dishes in a minimum volume of lysis
buffer (50 mM HEPES (pH 7.5), 150 mM NaCl, 1.0 mM EGTA, 30.0 mM p-
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nitrophenylphosphate, 1.0 mM sodium orthovanadate, 50.0 mM NaF, 1.0 mM
phenylmethylsulfonyl fluoride, 10.0 µg/ml aprotinin, and 10.0 µg/ml leupeptin). The
total protein concentration of the cell lysates was determined using a modified
Bradford assay (Bio-Rad Laboratories (CA)), and performed as described by the
manufacturer. Protein concentrations were determined so that we could load equal
amounts of protein into each well of the gel. Western Blotting was accomplished
using a NOVEX apparatus. A 12% acrylamide gel was used. The samples were
loaded, the gel was run at 130 V for 75 minutes, followed by transfer of the proteins
to a PVDF membrane at 65 V for one hour following the instructions provided by the
manufacturer. Membranes were blocked with freshly prepared PBS containing 3%
nonfat dry milk (PBS-milk) for 1 hour at room temperature with gentle agitation. The
membranes were then incubated overnight at 4°C with 1.0 µg/ml of a mouse
monoclonal IgG2 a primary antibody (Upstate Biotechnology, NY), directed against
p53, diluted in PBS-milk. The blot was washed the next day and then incubated with
the anti-IgG secondary antibody (Upstate Biotechnology, NY) linked to horseradish
peroxidase (goat anti-mouse IgG), diluted 1: 1000, for 1 hour at room temperature.
Next, the blot was washed and an enhanced chemiluminiscent (ECL) system
(Kirkegaard & Perry Laboratories, MA) was used for detection of proteins. We used
Jurkat cell lysate as positive control for p53 (human-T lymphocyte line, Upstate
Biotechnology, NY).
We have also tested for the amount of p21wafl protein in various samples using
the Western Blot technique. The primary antibody was Anti-Cipl/WAF-1/p21 mixed
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mouse monoclonal IgGs at 1 µg/ml (Upstate Biotechnology, NY) and the secondary
antibody was the same as above. A positive control for p21 was not available.
cDNA Expression Array
Cells in the logarithmic phase were treated with the different conditions
described in the Results section. Total RNA was isolated from cultured cells using a
commercially available kit from CLONTECH, the Atlas Pure total RNA labeling
system. The method consists of three rounds of phenol-chloroform extraction,
followed by precipitation of the RNA with isopropanol and centrifugation at 12,000
rpm. After centrifugation, the pellet was allowed to dry and resuspended in RNase
free water.
The quality of isolated RNA was determined in two ways. First 2 µl of sample
was dissolved in 398 µl buffer (10 mM Tris-pH 7.5 and 0.1 mM EDTA-pH 7.5) and
the A260 and A280 were read using a Beckman DU-7400 spectrophotometer. The buffer
was used as a reference blank. The A2601A280 ratio was then determined to ensure it
was between 1.9-2.1. The total A260 was calculated multiplying the A260 reading by the
dilution factor (200 in this case). Knowing that one A260 unit of RNA is 40 µg/ml, the
concentration (µg/ml) of the RNA in each sample was calculated by multiplying the
total A260 by 40 µg/ml. The RNA yield in milligrams was obtained by multiplying the
concentration by the volume of the RNA sample.
The RNA quality was also determined using an agarose gel. Five µg of RNA
was loaded onto a 1% agarose gel and run for 1 hour at 75 volts. The gel was washed
twice for 15 minutes in DEPC treated water, then the gel was incubated in ethidium
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bromide solution (lµg/ml) for 15 minutes followed by washing again twice for 15
minutes in DEPC treated water. Nondegraded RNA appeared as two bright bands
(23S and 16S ribosomal RNA) under UV light.
To eliminate genomic DNA, DNase treatment of total RNA (lmg/ml) was done
using 10 x DNase buffer and DNase I ( l unit/µl). For better results Ambion's ANTI
RNase (1 unit/µl) was included. For example, 500 µl of a RNA sample (lmg/ml),
100µ1 of 10 x DNase I Buffer, 50 µl of DNase I (1 unit/µl) and 350 µl of deionized
water were added together. After incubation for 30 minutes at 37°C, the reaction was
terminated using 100µ1 10 x Termination Mix. A phenol: chloroform extraction was
done next and then the samples were treated with 1/10 volume of2M sodium acetate
and 2.5 volumes of95% ethanol. After incubation on ice for 10 minutes, the samples
were centrifuged at 14,000 rpm for 15 minutes at 4°C. The pellet was then washed
with 80% ethanol, centrifuged at 14,000 rpm for 5 minutes at 4°C, and allowed to dry
for about 10 minutes. The precipitate was dissolved in RNase free water and the
purity and quality ofthe RNA checked again, as described above.
The next step was preparation of streptavidin magnetic beads. The magnetic
beads (15 µl are sufficient for one sample which contains up to 50 µg total RNA)
were washed three times in 150 µl of1 x Binding Buffer, then resuspended in 15 µ11
x Binding Buffer. Next, poly A+ enrichment was performed. For every 50 µg of total
RNA (diluted up to 45 µl with deionized water) 1 µl biotinylated oligo(dT) was added
and the mixture was incubated for 2 minutes at 70°C. The mixture was then cooled at
room temperature for 10 minutes followed by addition of45 µl of2 x Binding Buffer.
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Fifteen µl ofthe magnetic beads were then added to each RNA sample. The mixture
was then vortexed at the highest setting for 25-30 minutes and the beads were
separated using a magnetic particle separator. The beads were then washed in 50 µl of
1 x Washing Buffer. The wash was repeated two more times and the magnetic beads
were resuspended in 50 µl of 1 x Reaction Buffer. The Reaction Buffer was removed
and the beads were resuspended in 6 µl ofdeionized water.
For cDNA probe synthesis it was necessary to prepare a Master Mix which
contained 4µ1 of 5 x Reaction Buffer, 2 µl of 10 x dNTP mix, 5 µl of 32P-dATP
(3,000 Ci/mmol, 10 µCi/µl) and 0.5 µl of DTT ( 100 mM) per reaction. One µl of
CDS Mix (which contains primers) was then added to the resuspended beads (contain
the polyA+ RNA), and the samples were incubated at 65°C for 2 minutes, followed by
another 2 minutes incubation at 50°C. Meanwhile, 2 µl of MMLV Reverse
Transcriptase was added per reaction to the Master Mix. After the incubation of the
beads at 50°C, 13.5 µl ofthe Master Mix was added to each sample and the reaction
mixture incubated for 25 minutes at 50°C. The reaction was terminated by adding 2 µl
ofTermination Mix.
Purification of the labeled cDNA from unincorporated 32P-labeled nucleotides
and small cDNA fragments was accomplished by column chromatography. First the
beads were separated using the magnetic particle separator and the supernatant
(approximate 20 µl) was added to 180 µl ofNT2 Buffer. The sample was then placed
into a NucleoSpin Extraction Spin Column and centrifuged at 14,000 rpm for 1 min.
The content of the collection tube was discarded into the appropriate container for
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radioactive waste. The column was washed with 400 µl of NT3 Buffer and
centrifuged at 14,000 rpm for 1 minute. The content of the collection tube was
discarded into the appropriate container for radioactive waste. The washing with the
NT3 Buffer was repeated two more times. The NucleoSpin Column was treated with
100 µl of Buffer NE, allowed to soak for 2 minutes-and then centrifuged for 1 minute
at 14,000 rpm to elute the purified probe. The radioactivity of the probe was checked
by scintillation counting using a 2 µl aliquot in 5 ml of scintillation cocktail.
Hybridization of the cDNA probes to the membrane consisted of several steps.
To avoid nonspecific binding, the membrane was prehybridized with hybridization
buffer (supplied by CLONTECH) containing sheared salmon testes DNA (0.1mg
sheared salmon testes DNA/ml hybridization buffer). This solution was prepared by
first heating 2mg (210.52 µl) of sheared salmon testes DNA at 95-100°C for 5
minutes and then chilling it on ice. Next, 20 ml of hybridization buffer (prewarmed at
68 °C) was mixed with the sheared salmon testes DNA, to give a final of concentration
0.1 mg/ml. The membrane was then prehybridized for 30 minutes with the salmon
sperm DNA solution at 68°C with continuous agitation. Meanwhile 100 µl of cDNA
probe was treated with 5 µl of C0t-l DNA, incubated for 2 minutes in boiling water
bath, and then incubated on ice for exactly 2 minutes for DNA denaturation.
Following the prehybridization period, the probe was added carefully to the
prehybridization buffer, making sure that the concentrated solution was not added
directly to the membrane. The membrane was hybridized overnight with continuous
agitation, and the next day the membrane was washed 4 times with wash solution 1 (2
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x SSC-containing 0.3 M NaCl and 0.03M Na3 Citrate-2 H20, 1 % SDS) for 30 minutes
and once with wash solution 2 (0.1 SSC, 0.5% SDS) for 30 minutes. All washes were
done at 68°C. The final wash was for 5 minutes at room temperature with 2 x SSC.
The membrane was wrapped in plastic wrap and exposed to X-ray film for various
periods of time.

CHAPTER ill
RESULTS AND DISCUSSION
Glutathione S-Transferase Assay
The purpose of this set of experiments was to determine if the different
treatment conditions previously described produced an increase in activity of GST
since it was reported that both chromium (Dubrovskaya et al., 1998) and BPDE
(Hayes et al., 1995) induce GST activity. In performing the assay, the most widely
used substrate has been 1-chloro-2,4-dinitrobenzene (CDNB) because it has good
specificity for all isoenzymes of GST (Simons et al., 1977). When conjugated with
glutathione (GSH) it produces S-(2,4-dinitrophenyl) glutathione (Fig. 14), a
compound possessing an absorbance spectrum sufficiently different from that of
CDNB to allow for a simple spectrophotometric assay at 340 nm (Habig et al., 1981).

HCl

Fig. 14. Conjugation ofCDNB with GSH.
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Experiments were first conducted to validate the assay. Tumor cells (HTl 080)
were used initially because they grow much faster than normal human fibroblasts
(L266C) and allowed faster data collection. Purified glutathione S-transferase (stock
solution 0.2 mg/ml) was also used as a control to insure that the assay was working.
Initially, HTI 080 cells were plated onto 150 mm dishes, were allowed to grow, and
after they were nearly confluent, the cells were trypsinized, and a cell suspension was
made using 5ml PBS containing l mg/ml BSA. Sonication of the HT1080 cell
suspension was accomplished using 2x30 second bursts with the sonicator (50 Sonic
Dismembrator, model F50, Fisher Scientific) set on 10. The sonicator has settings 1
to 10, 1 corresponding to the lowest power and 10 corresponding to the highest
power. The GST activity in sonicated cells was then determined and compared to the
activity of pure enzyme which had not been sonicated. The results are presented in
Table 2. The blank contained 960µ1 of phosphate buffer and 40 µl of ethanol and the
average was substracted from each reading.
Table 2. GST Activity for Pure Enzyme and HTl 080 Lysate Sonicated at Setting 10
for 2x30 sec.
Setting of
Sonicator
10

Time (sec)

Sample

Units/ml

±S.D.

2x30

GST
HT1080 lysate

0.0692
0.0155

0.0051
0.0002

We compared the activity of the pure enzyme with the activity of a cell lysate
to see if we could measure activity in cells. Comparing the activity of the pure
enzyme (stock solution 0.2 mg/ml in phosphate buffer 0.2 M, pH 6.5) with the
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activity of the HTl 080 lysate, we observed that the activity of the lysate was much
lower. One possibility for this result was the fact that the sonication could be
destroying the enzyme. Another possibility is that the GST activity is low in this
particular cell line. To test if the sonication was destroying the enzyme, we repeated
the experiment, sonicating the pure enzyme on setting #10 for 2x30 sec. The results
shown in Table 3 clearly indicate that the sonication destroys enzyme activity. There
are several possibilities for the lose in activity. Either the power is too great, the
exposure time is too long, or both, and therefore, the activity of the enzyme due to
denaturation.
Table 3. GST Activity for Pure Enzyme and Pure Enzyme Sonicated at Settingl0 for
2x30 sec.
Setting of Sonicator
10

Time (sec)
2x30

Sample
GST
GST

Units/ml
0.0785
0.0041

±S.D.
0.0085
0.0005

We next tried to determine the best setting and time for the sonicator so that
the enzyme activity would not be affected, but all cell membranes would be lysed.
Initially, we used pure enzyme and chose different settings for the sonicator and
different sonication times (see Table 4). When we used setting #2 for 2x30 sec we
lost the activity of the enzyme indicating that the exposure time was too long. We
tried the same setting for 15 and 20 sec and the activity of the enzyme was preserved.
When we raised the sonicator setting to 4, we still had good activity for 2x15 sec. We
also tried the sonicator set at #6 for 2x15 sec and we were able to measure significant
activity. The conclusion from this set of experiments was that the activity of GST is
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maintained when the sonicator is set at #4 or #6 and a 15 second burst is used twice
(2x15 sec).
Table 4. GST Activity for Pure Enzyme Using Different Settings and Different
Sonication Times.

Setting of
Sonicator
2
2
2
2
4
4
6

Time (sec)
2x30
2x20
2x15
2x10
2x25
2x15
2x15

Sample

Units/ml

±S.D.

GST
GST
GST
GST
GST
GST
GST
GST

0.0703
0.0110
0.0653
0.0806
0.0756
0.0607
0.0901
0.0618

0.0020
0.0015
0.0015
0.0037
0.0054
0.0008
0.0039
0.0021

Next, we needed to check these settings and times using cell lysates. From one 150
mm dish of nearly confluent HT1080 cells we made a cell suspension as previously
described. Before sonication, we divided the sample into three equal aliquotes. GST
was determined for each in triplicate, using the sonicator set at #4 and a pulse time of
15 sec (Table 5, Set 1). Lysates were prepared using 2 other 150 mm dishes, and
analyzed in the same manner (Table 5, Set 2 and Set 3). We found that the activity of
GST was consistent for each set of cell samples showing that the assay gave
reproducible results for a single sample. The values of activity differ for different sets
of data because the number of cells per culture dish varies. An additional dish of cells
was used to prepare lysates using setting #6 pulsed 2x15 sec. The result of the GST
assay gave an activity of 0.1660 units/ml. Thus, increasing the setting did not increase

36
the activity. We concluded from this set of experiments that maximal cell lysis was
probably accomplished using setting 4 and the activity ofthe enzyme was preserved.
Table 5. GST Activity for HT1080 Cell Lysate Using Setting #4, 2x15 sec.

Set 1

Set 2

Set 3

Setting
of
Sonicator

Time
(sec)

4

2x15

4

2x15

4

2x15

4

2x15

4

2x15

4

2x15

4

2x15

4

2x15

4

2x15

Sample·
HT1080
lysate
HT1080
lysate
HT1080
lysate
HT1080
lysate
HT1080
lysate
HT1080
lysate
HT1080
lysate
HT1080
lysate
HT1080
lysate

Units/ml

±S.D.

0.1525

0.0100

0.1723

0.0048

0.1776

0.0041

0.0679

0.0055

0.0802

0.0085

0.0717

0.0066

0.1331

0.0005

0.1357

0.0022

0.1275

0.0008

We also performed some experiments to verify that the compounds we were
testing did not interfere with the assay. We first tested the absorption ofchromium at
the wavelength used in the assay to check if at 320 nm Cr (VI) does exhibit
absorption. The control contains 760 µl phosphate buffer (pH 6.5), 40 µl of CDNB,
100 µl ofGSH and 100 µl ofPBS. Chromium, at a final concentration of0.3 µM, was
added to the same mixture as the control and the assay was performed in triplicate for
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each condition. The results are presented in Table 6 and show that chromium does not
give significant absorbance under the conditions of our assay.
Table 6. Absorption of Cr at 340 run.
Sample

Units/ml

±S.D.

Control

0.0049

0.0005

Chromium

0.0047

0.0004

We next determined if the carcinogens we used affected the assay. This time
we used the normal human fibroblasts cell line L266C. Cells were grown, harvested
while in logarithmic growth, and lysed by the sonication procedure chosen above.
The lysate was used for determination of the activity of the enzyme in the presence
and absence of Cr and BPDE. The carcinogens were added to the lysate at a final
concentration of 0.3 µM (the same as we used when we treated cells with
carcinogens) and then the assay was performed. The results from two sets of
experiments are presented in Fig. 15 with error bars representing the range of the data
obtained. The activity of each sample is relative to the untreated control lysate which
have been defined as 100%. These experiments show that the glutathione S
transferase assay is not affected by Cr and/or BPDE at the concentrations we used in
the experiments to follow. Therefore, residual Cr and BPDE in the cell lysate should
not influence the GST assay.
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Fig. 15. Effect of Added Cr and BPDE on GST Activity.

Having established the assay, we performed experiments using normal human
fibroblasts (L266C cells). We set up the four conditions described in the Introduction
(control, chromium treated cells, BPDE treated cells, and cells treated with both
carcinogens). Cells in the logarithmic phase were trypsinized, washed off the dishes
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with PBS (with l mg/ml BSA) and lysed by sonication on setting #4 for 2x15 sec.
Three sets of experiments were performed and the results are presented in Fig. 16
with error bars representing the standard deviation. The conclusion from these
experiments is that glutathione S-transferase activity is not influenced by any of our
conditions.
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Fig. 16. GST Activity in Various Sonicated Cell Lysates.
We also performed the same experiment as in Figure 16 except usmg the
freeze/thawing method for preparing cell lysates. The cells were plated in 3 150 mm
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dishes per condition, and when they reached about 50% confluence, they were treated
using one of the four conditions previously described. Cells were harvested, and lysed
by three cycles freeze/thawing using a dry ice/ethanol bath. The experiment was
performed three times and the results are presented in Fig. 17 with error bars
representing the standard deviation. This set of experiments shows once again that the
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Fig. 17. GST Activity in Various Cell Lysates Prepared by the Freeze/thawing
Method.
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activity of glutathione S-transferase is not influenced by the different conditions of
treatment used in this study.
Some research groups have observed an increase of expression of hGSTPl-1
in cells treated with BPDE (Fields et al., 1998). For this particular study human T47D
cells (breast) were stably transfected with hGSTP-1. These investigators used a higher
concentration of BPDE 1.0 µMand a different exposure time (20 min) (Fields et al.,
1998) and found that expression of hGSTPl-1 protects against DNA damage induced
by BPDE. Since we could not express the GST activity as a function of protein in the
sample we cannot compare (numerically) our results with theirs. In addition, the cell
line that was used by Fields et al., T47D, was different from those used in this study.
Therefore, we don't know if GST can be induced in fibroblasts.
It has also been reported that Cr (VI) induces GST activity (Tully et al., 2000).
These workers used HepG2 cells and only found induction (6 fold) using 1 0 µMCr
(VI) for 48 hours, but not at concentrations of 5 µMor less. For this particular study
the exposure time was the same as the one we used, but they used a hepatoma cell
line. They did not measure GST activity but gene expression. Thus, comparisons of
activities cannot be made.
There are groups who have measured the GST activity in the same organ type
and the values reported are very different, even though they used the same method to
assay the activity of the enzyme. For example, Singh's group (Singh et al., 1998),
determined the GST activity in mice liver to be 470 nmol/min/mg protein while
Kim's lab (Kim et al., 1997), reported that the GST activity was 60 nmol/min/mg
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protein using the same tissue. These values correspond to the control cells in their
studies, so it would seem reasonable to compare. Therefore, the determined activities
reported in the literature vary considerably and one cannot speculate about the ability
of glutathione S-transferase to be induced in fibroblasts by chromium or BPDE based
upon literature values.
Cell Cycle Analysis
One hypothesis, that could explain the previous mutant frequency results
discussed in the Introduction, is that the cell cycle is halted at the G1/S boundary in
the presence of chromium and/or the BPDE and chromium so that DNA repair can
occur prior to DNA replication. To investigate this possibility, the incorporation of
tritiated thymidine into DNA was measured. Cells were treated as described in
Materials and Methods so that the four conditions were established (control,
chromium treated cells, BPDE treated cells, and chromium and BPDE treated cells).
Cells were assayed for 3 H-thymidine incorporation at 12, 16, 20, 24, 28, 32, 36 and
40 hours after release from confluence and the average and standard deviation for
triplicate samples were plotted. The results show that entry into S phase occurs after
about 30 hours for control cells (Fig. 18), cells treated with chromium (Fig. 19), cells
treated with BPDE (Fig. 20) and cells treated with both carcinogens (Fig. 21). This
data suggests that the cell cycle doesn't seem to be affected by the different
conditions since the entry into the S phase occurs at the same time for all conditions.
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Delay of S phase may not be the cause of the antagonistic effect of chromium on
relative mutant frequency ofBPDE.
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The results of this experiment are consistent with prev10us data from
laboratory (see Fig. 6). In previous experiments, control cells exhibited the highest
level of cloning and here, the control cells show the highest incorporation of 3 H
thymidine. Chromium treated and BPDE treated showed a reduction in cloning
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ability, and the reduction is mirrored in the incorporation of H-thymidine (Table 7).
3

The greatest effect on cloning is observed when cells are treated with both
carcinogens and we see the lowest incorporation under these conditions.
Table 7. Cell Cycle Analysis for Different Conditions.
SAMPLE

Maximal Incorporation (CPM)

CONTROL

6684.57 ± 2592.65

Cr

1937.50 ± 406.55

BPDE

729.40 ±130.10

Cr+BPDE

309.12 ± 15.57

Xu et al., performed studies to see if there is a delay in cell cycle when cells
are treated with Cr(VI). They used LL 24 cells, which are a fibroblast-like normal
human lung cell line. Treatment conditions were 0, 10, 50 and 200 µM Cr(VI) for 2
hours. Cells were harvested at 6, 24 and 48 hours after treatment. The samples were
analyzed on an EPICS Profile Flow Cytometer. They observed a slightly reduced
progression into S phase. We can say, however, that their results were obtained at
much higher chromium concentrations than we used in our study. Again it is difficult
to compare their results with ours since they used different concentrations, different
exposure times, and a different assay.
Binkova's laboratory focused on the effect of benzo(a)pyrene on human
embryonic lung diploid fibroblasts (HEL cells) (Binkova et al., 2000). The exposure
time was 24 hours using B(a)P at 1.0 µM. Data acquisition was performed using an
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argon laser fluorescence activated cell analyser. After 24 hours of treatment, there
was an increase in the proportion of cells which had entered the S phase compared to
controls. For the control they observed 88% of the cell population in the Go/G 1 phase
and 8% in S phase. The cells treated with B(a)P (0.10 µM), 84.5% cells were in the
Go/G1 phase and 12% were in S phase. Again, it is difficult to compare situations
when you use different cell lines, different concentrations, and exposure times.
However, one should note that the effects of cell cycle arrest were observed at BPDE
concentrations higher than those used in our study.
In the future, to see if our results are reproducible, the experiment can be
repeated using flow cytometry for data acquisition. Using the DNA labeling assay we
could follow only the transition to S phase, but by flow cytometry, you can get
information about the cell populations in various stages of the cell cycle.
p53 and p21 Protein Level
As discussed in the Introduction, chemical damage to DNA may not result in a
mutation if the DNA is repaired prior to replication (Bertram, 2001). There are
checkpoints in the cell cycle at the G 1 /S boundary to make sure that the DNA is
integer, and if not, the entry into the S phase may be delayed to allow more time for
DNA repair. It has been shown that an important role in halting the cell cycle at the
G1/S phase is played by p53, which induces the synthesis of p21, which inhibits the
formation of the Cyclin D: CDK4/CDK6 complex (Xu et al., 1996).
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Western blotting analysis was used to determine if p53 and p21 are induced
under various conditions in our system. Four conditions were established. Cells were
treated with either normal growth media for 48 hours (control), media containing 0.3
µM potassium dichromate for 48 hours, normal growth media for 46 hours followed
by media containing 0.3 µM BPDE for 2 hours (BPDE), or 46 hours with media
containing 0.3 µM potassium dichromate followed by 2 hours with media containing
both 0.3 µM chromium and 0.3 µM BPDE together. Cell lysates were prepared as
described in Materials and Methods, and the amount of total protein was determined
for each lysate to ensure that the same amount of protein was analyzed in each
condition. Western Blot analysis for p53 and p21 was performed as described in
Materials and Methods using 10 µg total lysate in each well of the gel. The amount of
protein loaded into the wells of the gel was low compared to other groups (Bink.ova et
al., 2000).Unfortunately we could not load more into the wells.
The results (Fig. 22), showed that the assay was working since the positive
control was visible, but no bands were seen in our samples. Only the positive control
for p53 protein was ever observed in any experiment. Molecular weight markers were
included on the gel to help us to identify the bands (not shown).
Unfortunately, when we probed for p21 nothing was detected. We could
not determine if the assay was working since we did not have an available positive
control. The reason that we did not observe any bands for p53 and p21 may be that
the level of protein expression was below the detectability of the assay. In the future,
a more concentrated lysate can be prepared or use immunoprecipitation can be used.

50
By precipitating the proteins of interest (p53 or p21) with antibodies directed against
them prior to running the gel. We did not attempt this because we moved on to the
microarray assay which contained both p21 and p53.

1

4

5

Fig. 22. Western Blot Analysis ofp53 Expression. Lane l was loaded with the
positive control for p53 and the remaining samples were loaded as follows: lane #2 control lysate, lane #3-Cr treated cell lysate, lane #4-BPDE treated cell lysate and
lane #5-both carcinogens treated cell lysate.
As with GST induction, we were not able to duplicate results previously
reported by others. Bink.ova and collaborators using human embryonic lung diploid
fibroblasts (HEL) observed an induction ofp53 after treatment with 1.0 µM B(a)P for
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24 h (Binkova et al., 2000). Again, the conditions used by these investigators resulted
in a much greater exposure than what we have used in our studies.
General Gene Expression
When proteins are expressed at low levels, an alternative is to look at the gene
expression. The purpose of the following experiments was to determine if there are
genes that are induced or suppressed by our different conditions. For these
experiments, we used a commercially available kit (Atlas Select Human Tumor Array
from Clontech CA), which contains 437 differentially expressed cDNAs including
p53 and p21. The array also contains 61 novel sequences, 32 cDNAs from genes with
established importance in cancer, 16 having partial homology to known sequences, 9
having homology to known ESTs (Expressed Sequence Tags), and 365 other known
genes. There are also housekeeping genes like ubiquitin, phospholipase A2, a
tubulin, 13-actin and glucose-3-phosphate dehydrogenase (G3PDH) spotted on the
membrane.
One set of cells was treated for 46 hours with media containing potassium
dichromate followed by 2 hours with media containing both chromium and BPDE
and another set of cells was treated with normal growth media for 48 hours (control).
The RNA was isolated from the cells as described in Materials and Methods. The
A26012so ratio was 2.00 for the control cell RNA and 2.03 for the RNA from cells
treated with both carcinogens. The quality of the RNA was checked by running a gel
and the samples were compared with previous samples prepared using a different
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protocol for RNA isolation (GIBCO BRL-Life Technologies- TRizol reagent). Ten
µg of RNA was loaded in each well. It was necessary to isolate the RNA using the
CLONTECH protocol because other commercially available kits for RNA isolation
are not compatible with this array, resulting in a high level of nonspecific
background. The gel is presented in Fig. 23 and shows that the quality of RNA
isolated is good.
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2

3

4

28 S

18 S

Fig. 23. RNA Purity Following Isolation (1). The lanes were loaded as follows:
control (1) and both carcinogen treatment (2) from using TRizol reagent and control
(3) and both carcinogen treatment (4) from samples using the CLONTECH protocol.
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Fig. 24. RNA Purity Following DNase Treatment. The lanes were loaded as follows:
control (1) and both carcinogen treatment (2) from using TRizol reagent and control
(3) and both carcinogen treatment (4) from samples using the CLONTECH protocol
after the DNase treatment.
Next, the samples were treated with DNase as described by the
manufacturer and the quality of the RNA checked. The A26012so ratio was 2.04 for the
control cell RNA and 2.02 for the RNA from cells treated with both carcinogens. A
picture of this gel is presented in Fig. 24. As we can see, a smear appears in the
DNase treated samples instead of the bands meaning that the RNA was degraded
during the DNase treatment.
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To solve this problem, we incubated the RNA samples with DNase 1 and
ANTI-RNase (Ambion, TX), at a concentration 1 unit/µl. Fig. 25 shows the samples
before DNase treatment. Five µg of RNA were loaded in each well. The A26012so ratio
was 2.17 for the control cell RNA and 1.95 for the Cr+BPDE cell RNA.

1

2

28 S
18 S

Fig. 25. RNA Purity Following Isolation (2). The first lane is the control RNA
sample (1) and the second lane is RNA isolated from both carcinogen treatment (2).
The RNA following the DNase treatment using Ambion's ANTI-RNase is
presented in Fig 26. Five µg of RNA were loaded in each well. The A26012so ratio was
2.37 for the control RNA and 2.22 for Cr+BPDE treated cell RNA. We can see from
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Fig. 26 that the quality of RNA after DNase treatment is significantly better when the
DNase treatment is done in the presence of Ambion ANTI-RNase.

1

2

3

28 S

18 S

Fig. 26. RNA Purity Following DNase Treatment in the Presence of Ambion ANTI
RNase. The first lane is a positive control from an old sample (1), the second lane is
the control RNA sample after DNase treatment in the presence of Ambion ANTI
RNase. (2) and the third lane is RNA isolated from both carcinogen treatment after
DNase treatment in the presence of Ambion ANTI-RNase (3).
Once the RNA degradation problem was solved we proceeded to make probes
from our RNA. To verify the probe labeling procedure, we synthesized cDNA from
our two samples as described in Materials and Methods, as well as, from a control
RNA provided by the manufacturer which contains a 1: 1: 1 mixture of human, mouse
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and rat total RNA. An aliquot of 2 µl of each sample was diluted in 5 ml of
scintillation liquid and counted. The counts for the three samples are presented in
Table 8. The results, shown in Table 8, indicate significant incorporation of label into
all three samples.
Table 8. Labeling of cDNA Probe.
Sample

Counts/min (CPM)

Control RNA/Company

40302.0

Control Sample RNA

46591.0

Cr+BPDE Sample RNA

28838.0

It was also necessary to verify that we could hybridize the cDNA probes onto
the membranes. The company provided Control PolyA+ RNA. After making labeled
probe from this RNA, the probe was hybridized to the membrane. The amount of
+
radiation incorporated into the probe for the control PolyA RNA was 354368.0

counts/min (CPM). Notice that the amount of radiation incorporated is about 10 times
more than that of our samples, but the protocol predicted better incorporation for the
+
control polyA . The probe was then hybridized to the Atlas membrane as described in

Materials and Methods. Following hybridization, the membrane was washed and
exposed to film for three days (see Fig. 27).

We were not able to see the

housekeeping genes which help to orient the film on the grid to identify other genes
of interest as in Fig. 28. (G1-G21). Fig. 29 shows the results of a membrane exposed
for three days using an Atlas Human cDNA expression array and Human Control
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polyA . The darker dots on the bottom and right side are the housekeeping genes,
+

which help to orient the film onto the grid. Notice that for this example there were
double spots for each gene, but for the tumor array we used there should be single
spots.
We did attempt to hybridize the probes made from our samples to the
membranes. The signals for the control cells and cells treated with both carcinogens
were too weak, and only four dots were visible after 3 days of exposure. Thus, we
have not able to identify differences between the two conditions tested using this
assay.
Using the Atlas Select Tumor Array we tried to identify genes that are turned
on/off by our different treatments. Unfortunately, the hybridization of the cDNA
probe to the membrane was not good and we could not observe a signal. This may
have been because we did not use enough hybridization buffer. We used only 5 ml as
described in the instructions, but used a larger hybridization bottle. Another reason
may be that the membranes were used several times and they lost their quality. We
were also not sure about the quality of the cDNA probe synthesized. When we check
it by running an agarose gel, we observed most of the label at the bottom of the gel,
indicating very small pieces. Maybe this problem can be overcome if we try to reduce
the RNA degradation by adding 100 units of Ambion's ANTI-RNase after adding the
magnetic beads to the RNA sample.
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Fig. 27. Analysis of Control RNA.
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Fig. 28. Grid for the CLONTECH Atlas Select Human Tumor Array.

Fig. 29. Example of Results Obtainable Using Atlas Select Array System.

CHAPTERIV
CONCLUSION

The purpose of this study was to determine what protective mechanisms may
be triggered in cells in response to multiple carcinogen treatment. First we tested if
the enzyme glutathione S-transferase, which is involved in detoxification of a wide
variety of chemicals, is induced by our treatments. We prepared cell lysates using two
methods (sonication and freeze/thawing method), but we could not observe any
significant increases in GST activity for any of our treatments.
We also tested if the different treatments with carcinogens had an effect on the
cell cycle. Using tritiated thymidine we performed DNA labeling experiments for the
four conditions and observed that cells enter S phase at about the same time,
regardless of the treatment.
We were not able to come to any conclusions from the gene array experiments
since our hybridizations did not give strong enough signals.
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APPENDIX

Statistical analysis was done for the GST experiments using the two-way
RGLM ANOVA. For all the experiments tested, the p value was larger than .05.
Thus, the conclusion is that the results for different treatments have no statistically
significance difference in induction of GST compared to the control.

61

BIBLIOGRAPHY
Aiyar, J., Borges, K. M., Floyd, R. A., Wetterhahn, K. E., (1989). Role of chromium
(V), glutathionethiol radical, and hydroxyl radical intermediates in chromium
(VI)-induced DNA damage. Toxicol. Environ. Chem., 22, 135-145.
Albrechtsen, N., Dornreiter, I., Grosse, F., Kim, E., Wiesmilller, L., Deppert, W.,
(1999). Maintenance of genomic integrity byp53: complementary roles for
activated and nonactivated p53. Oncogene, Vol. 18, 53, 7706-7717.
Anderson, A. R., (1997). Chromium as an essential nutrient for humans. Regulatory
Toxicology and Pharmacology, 26, S35-S41.
Bertram, J. S, (2001). The molecular biology of cancer, Molecular Aspects of
Medicine, 21,167-233.
Binkova, B., Giguere, Y., Rossner Jr., P., Dostal, M., Radim, J. S. (2000). The effect
of dibenzo[a,l]pyrene and benzo[a]pyrene on human diploid lung fibroblasts:
the induction of DNA adducts, expression of p53 and p21WAFl proteins and
cell cycle distribution. Mut. Res., 471-1-2, 57-70.
Bradford, M., (1976). A rapid and sensitive method for the quantification of
microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem., 72, 248-254.
Burke, T., Fagliano, J., Goldoft, M., Hazen, R. E., Inglewicz, R., McKee, T., (1991).
Chromite ore processing residue in Hudson County, New Jersey. Environ.
Health Perspect., 92, 31-137.
De Flora, S., Bagnasco, M., Serra, D., and Zanacchi, P. (1990). Genotoxicity of
chromium compounds: A review. Mutat. Res., 238, 99-172.
Denissenko, M. F., Pao, A., Pfeifer, G. P., Tang, M., (1998). Slow repair of bulky
DNA adducts along the nontranscribed strand of the human p53 gene may
explain the strand bias of transversion mutations in cancers. Oncogene, 16,
1241-1247.
Dictor, M., Ehinger, M., Mertens, F., Akervall, J., Wennerberg, J., (1999). Abnormal
cell cycle regulation in malignancy. Am. J. Clin. Pathol., 112 -1, S40-S52.

62

63
Draetta, G. F., (1994). Mammalian Gl cyclins. Curr. Opin Cell Biol., 6, 842-846.
Dubrovskaya, V. A., Wetterhahn, E., (1998). Effects of Cr (VI) on the expression of
the oxidative stress genes in human lung cells. Carcinogenesis,18- 8, 14011407.
Ekholm, S. V., Reed, S.I., (2000). Regulation of G 1 cyclin-dependent kinases in the
mammalian cell cycle. Curr. Opin Cell Biol., 12, 676-684.
Parser, M. C., Tucker, M. A., (1989). Second malignancies following cancer therapy.
Semin. Oncol. Nurs., 5, 43-55.
Fields, W. R., Morrow, C. S., Doss, A. J., Sundberg, K., Jernstrom B., Townsend, A.
J., (1998). Overexpression of stably transfected human glutathione -S
transferase Pl-lprotects against DNA damage by benzo(a) pyrene diol epoxide
in human T47D cells. Molecular Pharmacology, 54, 298-304.
Fisher, R. P., Morgan, D. 0., (1994). A novel cyclin associates with MO15/CDK7 to
form CDK-activating kinase. Cell, 78, 713-724.
Giaccia, A. J., Kastan M. B., (1998). The complexity of p53 modulation: emerging
patterns from divergent signals. Genes Dev., 12, 2973-2983.
Grana, X., Garriga, J., Mayol, X., (1998). Role of the retinoblastoma protein family,
pRb, p107 and p130 in the negative control of cell growth. Oncogene, 17, 33653383.
Habig, W. H., Pabst, M. J., Jakoby, W. B., (1974). Glutathione S-transferases the first
enzymatic step in mercapturic acid formation. J. Biol. Chem., Vol 249, 22,
7130-7139.
Habig, W.H., Jakoby, W. B., (1981). Assays for differentiation of glutathione-S
transferases, Methods Enzymol., 77, 398-405.
Hall, L., Angele S., (1999). Radiation, DNA damage and cancer, Mol. Med. Today, 5,
157-164.
Harbour, J. W., Luo, R. X., Dei Santi, A., Postigo, A. A., Dean D. C., (1999). Cdk
phosphorylation triggers sequential intramolecular interactions that
progressively block Rb functions as cell move through G 1• Cell, 98, 859-869.
Hayes, J. D., Pulford, D. J., (1995). The glutathione-S-transferase supergene family:
regulation of GST and the contribution of the isoenzymes to cancer
chemoprotection and drug resistance. Critical Reviews in Biochemistry and
Molecular Biology, 30-6, 445-600.

64
Hengstschlager, M., Braun, K., Soucek, T., Miloloza, A., Hengstschlager-Ottand, E.,
(1998). Cyclin-dependent kinases at the G1-S transition of the mammalian cell
cycle. Mutat. Res., 436, 1-9.
Hesse, S., Jernstrom, B., Martinez, M., Christodoulides, L., Ketterer, B.,
(1982).Inactivation of DNA-binding metabolites of benzo(a)pyrene-7,8dihydrodiol by glutathione and glutathione-s-transferase. Carcinogenesis, 3,
757-760.
Hickman, E.S., Moroni, C. M., Helin, K., (2002). The role of p53 and pRB in
apoptosis and cancer. Current Opinion in Genetics & Development, 12, 60-66.
Hu, X., O'Donnell, R., Srivastava, S., Xia, H., Zimniak, P., Nanduri, B., Bleicher, R.
J., Awasthi, S., Awasthi, Y. C., Ji, X., Singh, S. V., (1997). Active site
architecture of polymorphic forms of human glutathione-S-transferase P1-1
accounts for their enantioselectivity and disparate activity in the glutathione
conjugationof7�,8a-dihydroxy-9a,10a-oxy-7,8,9,10- tetrahydrobenzo(a)pyrene.
Biochemical and Biophysical Research Communications, 235, 424-428.
Hu, X., Herzog, C., Singh, S. V., (1999). Differential protection against
benzo(a)pyrene-7,8-dihydrodiol-9, 10-epoxide-induced DNA damage in HepG2
cells stably transfected with allelic variants of 1t class human glutathione-S
transferase. Cancer Res., 59, 2358-2362.
Iersel, M. L. P. S., Verhagen, H., Bladeren, P., (1999). The role of biotransformation
in dietary (anti0carcinogenesis. Mut. Res., 443, 259-270.
Kim, H. S., Lee, B. M., (1997). Inhibition of benzo(a)pyrene-DNA adduct formation
by Aloe brbadensis Miller. Carcinogenesis, 18-4, 771-776.
Kitahara, A., Satoh, K., Nishimura, K., Ishikawa, T., Ruike, K., Sato, K., Tsuda, H.,
Ito, N., (1984). Changes in molecular forms of rat hepatic glutathione-S
transferase during chemical hepatocarcinogenesis. Cancer. Res., 44, 2698-2703.
Kortenkamp, A., Casadevall, M., Faux, S. P., Jenner, A., Shayer, r.O., Woodbridge,
N., o'Brien, P.,(1996). A role of molecular oxygen in the formation of DNA
damage during the reduction of the carcinogen chromium (VI) by glutathione.
Archives of Biochemistry and Biophysics, 329, 199-207.
Lakin, N. D., Jackson, S. P., (1999). Regulation of p53 in response to DNA damage.
Oncogene, 18, 7644-7655.
Langard, S., (1990). One hundred years of chromium and cancer: A review of
epidemiological evidence and selected case reports. Am. J. Ind. Med., 17, 189215.

65
Leibross R.H. and Wetterhahn, K. E, (1990). In vivo formation of Cr (V) in chick
embryo red blood cells. Chem. Res. Toxicol., 3, 401-403.
Liu, W., Midgley, C., Stephen, C., Saville, M., Lane, D. P., (2001). Biological
significance of a small highly conserved region in the N terminus of the p53
tumor suppressor protein. J. Mol. Biol., 313, 711-731.
Luo, H., Lu, Y., Mao, Y., Shi, X., Dalal., N. S., ( 1996). Role of Chromium (IV) in
the Chromium (VI)- Related free radical formation, dG hydroxylation, and
DNA damage. Journal of Biochemistry. 64, 25-35.
Miksche, L. W., Lewalter, J., (1997). Health surveillance and biological effect
monitoring for chromium-exposed workers. Regulatory Toxicology and
Pharmacology. 26, S94-S99.
Miller, J. A., Miller, E. C., (1975). Metabolic activation and reactivity of chemical
carcinogens. Mutat. Res., 33, 25-26.
Mol, C. D., Parikh, S. S., Putnam, C. D., Lo. T. P., Tainer, J. A., (1999). DNA repair
mechanisms for the recognition and removal of damaged DNA bases. Annu.
Rev. Biophys. Biomol. Struct., 28, 101-128.
Morgan, D. 0., (1997). Cyclin-dependent kinases: engines, clocks, and
microprocessors. Annu. Rev. Cell Dev. Biol., 13, 753-756.
Nagata, S., (1997). Apoptosis by death factor. Cell, 88, 355-365.
Pavletich, N. P., (1999). Mechanism of cyclin-dependent kinase regulation: structures
of Cdks, their cyclin activators, and Cip and INK inhibitors, J. Mol. Biol., 287,
821-828.
Perlow, R., Broyde, S., (2001). Evading the proofreading machinery of a replicative
DNA polymerase: induction of a mutation by an environmental carcinogen....1,_
Mol. Biol., 309, 519-536.
Penning, T.M., (1993). Dihydrodiol dehydrogenase and its role in poycyclic aromatic
hydrocarbon metabolism. Chemico-Biological Interactions, 89, 1-34.
Siedegard, J., Ekstrom, G., (1997). The role of human glutathione S-transferases and
epoxide hydrolases in metabolism of xenobiotics. Environ. Health, 105 -4, 791799.

66
Shi, X., Chiu, A., Chen, C. T., Halliwell, B., Castranova, V., Vallyathan, V., (1999).
Reduction of chromium (VI) and its relationship to carcinogenesis. J. Toxicol.
Environ. Health, B 2, 87-104.
Shi, X., Dalal, N. S., Kasprzak, K. S., (1993). Generation of free radicals from
hydrogen peroxide and lipid hydroperoxides in the presence of Cr (III).
Archives of Biochemistry and Biophysics, 302-1, 294-299.
Shenberger, J. S. and Dixon, P. S., (1999). Oxygen induces S-phase growth arrest and
increases p53 and p21WAFl/CIPl expression in human bronchial smooth
muscle cells. Am. J. Respir. Cell Mol. Biol., 21, 395-402.
Sieleski, T. M., Boylan, J. F., Benfield, P. A., Trainor, G. L., (2000). Cyclin
dependent kinase inhibitors: useful targets in cell cycle regulation. Journal of
Medicinal Chemistry, 43-1, 1-14.
Simons, P. C. and Vander Jagt, D. L., (1977). Purification of glutathione-S
transferases from human liver by glutathione-affinity chromatography.
Analytical Biochemistry, 82, 334-341.
Singh, S. V., Hu, X., Srivastava, S. K., Singh, M., Xia, H., Orchard, J. L., Zaren, H.
A., (1998). Mechanism of inhibition of benzo(a)pyrene-induced forestomach
cancer in mice by dietary curcumin. Carcinogenesis, 19-8,1357-1360.
Srivastava, S. K., Hu, X., Xia, H., Awasthi, S., Amin, S., Singh, S., (1999). Metabolic
fate of glutathione conjugate of benzo(a)pyrene-(7R,8S)-diol (9S,10 R)
epoxide in human liver. Archives of Biochemistry and Biophysics, 371-2, 340344.
Sugiyama, M., (1991). Effect of Vitamins on Cr (VI) induced DNA-damage. Environ.
Health Perspect., 92, 63-70
Sugiyama, M., (1992). Role of physiological antioxidants in chromium (VI) - induced
cellular injury. Free Radical Biol. Med., 12, 397-407.
Tesfai, Y., Davis, D., Reinhold, D. S., (1998). Chromium can reduce the mutagenic
effects of benzo(a)pyrene diolepoxide in normal human fibroblasts via an
oxidative stress mechanism. Mutat. Res., 416, 159-168.
Tully, B. T., Collins, B. J., Overstreet, D. J., Smith, C. S., Dinse, G. E., Mumtaz, M.
M., Chapin, r. E., (2000). Effects of arsenic, cadmium, chromium and lead on
gene expression regulated by a battery of 13 different promoters in recombinant
HepG2 cells. Toxicology and Applied Pharmacology, 168, 79-90.

67
U.S. Public Health Service (1953). Health of workers in chromate producing
industry, U.S. Department of Health Education, and Welfare Publication 192,
U.S. Gov. printing Office, Washington, DC.
Vanhaecke, T., Vercruisse, A., Rogiers, V., (1997). Effect of pyruvate on glutathione
S-transferase expression in primary cultures of rat hepatocytes. Toxicology in
vitro, 11, 435-441.
Vincent, J.B., (2000). The bioinorganic chemistry of chromium. Polyhedron, 20, 126.
Wang, D., Kreutzer, D. A., Essigmann, J. M., (1998). Mutagenicity and repair
oxidative DNA damage: insights from studies using defined lesions. Mutat.
Res., 400, 99-115.
Watanabe, M., Maher, V. M., and McCormick, J. J., (1985). Excision repair of UV-or
benzo(a)pyrenediolepoxide-induced lesions in xeroderma pigmentosum variant
cells is "error-free". Mutat. Res., 146, 285-294.
Weintraub, S. J., Chow, K. N., Luo, R. X., Zhang, S. H., He, S., Dean, D. C., (1995).
Mechanism of active transcriptional repression by the retinoblastoma protein.
Nature, 375, 812-815.
Wiegand, H. J., Ottenwalder, H., Bolt, H. M., (1984). The reduction of chromium
(VI) to chromium (III) by glutathione; an intracellular redox pathway in the
metabolism of the carcinogen chromate. Toxicology. 33, 341-348.
Wilce, M. C. J., Parker, W., (1994). Structure and function of glutathione S
transferases. Biochimica et Biophysica Acta, 1205, 1-18.
Woods, J. S., Kavanagh, T. J., Corral, J., Reese, A., Diaz, D., Ellis, M. E., (1999).
The role of glutathione in chronic adaptation to oxidative stress: studies in a
normal rat kidney epithelial (NRK52E) cell model of sustained upregulation of
glutathione biosynthesis. Toxicology and Applied Pharmacology. 160, 207-216.
Wu, F., Wu, W., Kuo, H., Liu, C., Wang, R., Lai, J., (2001). Effect of genotoxic
exposure to chromium among electroplating workers in Taiwan. The Science of
the Total Environment, 279, 21-28.
Tyrcha, J., (2001). Age-dependent cell cycle models. J. Theor. Biol., 213, 89-101.
Xia, H., Pan, S. S., Hu, X., Srivastava, S. K., Pal, A., Singh, S. V., (1998). Cloning,
expression, and biochemical characterization of a functionally novel alpha class
glutathione-S-transferase with exceptional activity in the glutathione

68
conjugation of (+)-Anti-7,8-dihydroxy-9,10-oxy-7,8,9,10-tetrahydrobenzo(a)
pyrene. Archives of Biochemistry and Biophysics,. 353, 337-348.
Xu, J., Bubley, G. J., Detrick, B., Blakenship, L.J., and Patierno, S. R. (1996).
Chromium (VI) treatment of normal human lung cells results in guanine
specific DNA polymerase arrest, DNA-DNA cross-links, and S-phase blockade
of cell cycle. Carcinogenesis, 17, 1511-1517.

